| Document Date: 2014-10-09 14:57:02
Open Document File Size: 81,44 KBShare Result on Facebook
City Danbury / Valencia / New York / Paris / / Company Genzyme / MannKind Corporation / Greenhill & Co. / Sanofi / / Country United States / / Currency USD / / / Event FDA Phase / Business Partnership / Conference Call / Company Listing Change / / IndustryTerm manufacturing facility / manufacturing costs / telephone replay / integrated diabetes solutions / conference call / healthcare / blood glucose monitoring devices / manufacturing capacity / pharmaceuticals / drug-device combination product / diabetes management / drug delivery systems / therapeutic solutions / consumer healthcare / therapeutic products / diabetes solutions / / MedicalCondition integrated diabetes / Chronic Lung Disease Acute bronchospasm / COPD / diabetic ketoacidosis / hypersensitivity / hypoglycemia / asthma / acute bronchospasm / active lung cancer / pulmonary function / chronic obstructive pulmonary disease / diabetes / pain / Lung Cancer / diabetes mellitus / Heart Failure / chronic lung disease / diseases / irritation / potential lung disease / cough / Hypokalemia / pulmonary symptoms / / MedicalTreatment drug delivery systems / insulin therapy / insulin delivery / / Organization U.S. Food & Drug Administration / Securities and Exchange Commission / / Person Pierre Chancel / Alfred Mann / / / Position Chairman and Chief Executive Officer / exclusive financial advisor / global healthcare leader / Senior Vice President Diabetes Division / leader in diabetes management / / Product Afrezza / Afrezza® (insulin human) / Afrezza Inhalation Powder / / ProvinceOrState Connecticut / California / / Technology therapeutic solutions / drug delivery / / URL www.mannkindcorp.com / /
SocialTag |
PRESS RELEASE Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin Paris and Valencia, Calif. - August 11, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) and Ma